1) Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, Okumura K, Kato T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Nakaya H, Nakayama T, Hirai M, Fukatani M,
Mitamura H, Yamazaki T; J-RHYTHM Investigators. Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J. 2003;67:738-41

2) Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K, Inoue H. Rate control and quality of life in patients with permanent atrial fibrillation. Circ J. 2006;70:965-70

3) Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, Okumura K, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura
H,Yamazaki T, Watanabe E; The J-RHYTHM II Investigators. Randomized Study of Angiotensin II Type 1 Receptor Blocker vs Dihydropiridine Calcium Antagonist for the Treatment of Paroxysmal Atrial Fibrillation in Patients With
Hypertension. Circ J. 2006;70:1318-21

4) Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, Aizawa Y, Yamashita T, Atarashi H, Horie M, Ohe T, Doi Y, Shimizu A, Chishaki A, Saikawa T, Yano K, Kitabatake A, Mitamura H, Kodama I, Kamakura S. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. Int J Cardiol. 2009;137:102-7.

5) Ogawa S Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, Ohe T, Ohtsu H, Okumura K, Katoh T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Tabuchi T, Nakaya H, Nakayama T, Hirai M,
Fukatani M, Mitamura H for the J-RHYTHM Investigators. Optimal treatment strategy in patients with paroxysmal atrial fibrillation. Circ J 2009;73:242-248

6) Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, Inoue H, Ito M, Katoh T, Kobayashi Y, Koretsune Y, Kumagai K, Niwano S, Okazaki O, Okumura K, Saku K, Tanabe T, Origasa H and the J-BAF Investigators. Dose-response
effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms. Circ J. 2009;73:1020-1027

7) Aizawa Y, Kohsaka S, Suzuki S, Atarashi H, Kamakura S, Sakurai M, Nakaya H, Fukatani M, Mitamura H, Yamazaki T, Yamashita T, Ogawa S and J-RHYTHM Investigators. Comparison of Antiarrhythmics Used in Patients With Paroxysmal Atrial
Fibrillation. Circ J. 2010;74.:71-76

8) Endo A, Kohsaka S, Suzuki S, Atarashi H, Kamakura S, Sakurai M, Nakaya H, Fukatani M, Mitamura H, Yamazaki T, Yamashita T, Ogawa S; J-RHYTHM Investigators. Impact of drug alteration to maintain rhythm control in paroxysmal atrial
fibrillation. - Subanalysis from J-RHYTHM study -. Circ J. 2010;74:870-5

9) Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H for the J-RHYTHM Registry Investigators. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation?The J-RHYTHM
Registry study design. J Cardiol 2011;57:95-99

10) Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H,
Yamazaki T, Watanabe E, Ogawa S; on behalf of the J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with
hypertension (J-RHYTHM II Study). Europace. 2011;13:473-479.

11) Watanabe E, Yamashita T, Suzuki S, Saikawa T, Hirai M, Yamazaki T, Ohtsu H, Ogawa S, J-RHYTHM investigators. Statin treatment for patients with paroxysmal atrial fibrillation: A J-RHYTHM substudy. Int Heart J 2011;52:103-106

12) Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H; The J-RHYTHM Registry Investigators. Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation. Circ J. 2011;75:1328-33

13) Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, Hatayama T, Horiuchi D, Tsushima E. Time in therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation ? a multicenter
study of its status and influential factors ? Circ J 2011;75:2087-94

14) Suzuki T, Yamazaki T, Ogawa S, Nagai R, Yamashita T; J-RHYTHM II investigators. Echocardiographic predictors of frequency of paroxysmal atrial fibrillation (AF) and its progression to persistent AF in hypertensive patients with
paroxysmal AF: results from the Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II) Study. Heart Rhythm. 2011;8:1831-6

15) J-RHYTHM Registry Investigators. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation in Japan ? subanalysis of the J-RHYTHM Registry. Circ J 2011;75:2357-2362
16) Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, Uchiyama S, Matsumoto M, Ogawa S. Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial
Fibrillation. Circ J. 2012;76:1840-7.

17) Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S,
Fukatani M, Saikawa T, Chishaki A; J-RHYTHM Registry Investigators. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results
of the J-RHYTHM Registry. Circ J. 2013;77:2264-70.

18) Yamashita T, Inoue H. Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study. J Cardiol. 2013 ;62:50-7.

19) Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Urgent management of rapid heart
rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77:908-16.

20) Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, ?pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM;
ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104

21)Inoue H, Atarashi H, Okumura K, Yamashita T, Kumagai N, Origasa H. Thromboembolic events in paroxysmal vs. permanent non-valvular atrial fibrillation. Subanalysis of the J-RHYTHM Registry. Circ J. 2014;78(10):2388-93.

22)Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H; J-RHYTHM Registry Investigators. Validation of CHA₂DS₂-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. Circ J. 2014;78(7):1593-9. 

23）Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. Adv Ther. 2014 Apr;31(4):426-39. 

24）Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, Mercuri M, Ruff CT, Giugliano RP. Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin--Insights From the ENGAGE AF-TIMI 48 Trial. Circ J. 2015;79(12):2560-7.

25）Yamashita T, Horinaka S, Matsuhashi N, Suzuki N, Suzuki S, Ohtsuka T, Sagara K. Relation between frequency of activated partial prothrombin time measurements and clinical outcomes in patients after initiation of dabigatran: A two-center cooperative study. J Arrhythm. 2015 Feb;31(1):18-21. 

26）Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Use of warfarin in elderly patients with non-valvular atrial fibrillation -- subanalysis of the J-RHYTHM Registry. Circ J. 2015;79(11):2345-52. 

27）Tomita H, Okumura K, Inoue H, Atarashi H, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Assessment of risk factors for bleeding in Japanese patients with non-valvular atrial fibrillation receiving warfarin treatment: A subanalysis of the J-RHYTHM Registry. Int J Cardiol. 2015 Dec 15;201:308-10. 

28）Chishaki A, Kumagai N, Takahashi N, Saikawa T, Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M; J-RHYTHM Registry Investigators. Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry. Thromb Res. 2015 Aug;136(2):267-73. 

29）Ogawa H, Akao M, Suzuki S, Yamashita T, Okumura K, Atarashi H, Inoue H. Antiplatelet therapy in Japanese patients with atrial fibrillation without oral anticoagulants: Pooled analysis of Shinken Database, J-RHYTHM registry and Fushimi AF registry. Int J Cardiol. 2015;190:344-6. 

30）Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circ J. 2015;79(7):1486-95. 

31）Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T; J-RHYTHM Registry Investigators. Target intensity of anticoagulation with warfarin in Japanese patients with valvular atrial fibrillation – subanalysis of the J-RHYTHM Registry. Circ J. 2015;79(2):325-30. 

32）Yamashita T, Saitoh T, Matsushita M. Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. J Cardiol. 2015 Jul;66(1):69-72. 

33）Yamashita T, Inoue H, Okumura K, Atarashi H, Origasa H; J-RHYTHM Registry Investigators. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis. J Cardiol. 2015Mar;65(3):175-7. 

34）Inoue H, Kodani E, Atarashi H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Impact of Body Mass Index on the Prognosis of Japanese Patients With Non-Valvular Atrial Fibrillation. Am J Cardiol. 2016 Jul 15;118(2):215-21. 

35）Inoue H, Atarashi H, Kodani E, Okumura K, Yamashita T, Origasa H, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M, Saikawa T, Chishaki A; J-RHYTHM Registry Investigators. Regional Differences in Frequency of Warfarin Therapy and Thromboembolism in Japanese Patients With Non-Valvular Atrial Fibrillation　- Analysis of the J-RHYTHM Registry. Circ J. 2016 Jun 24;80(7):1548-55. 

36）Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 May 20;5(5). pii: e003432.

37）Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, Yamashita T, Ohnishi M, Yagi N, Fukaya T; J-Dabigatran Surveillance Investigators. Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance. J Arrhythm. 2016 Apr;32(2):145-50. 

38）Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation　- Results of the J-RHYTHM Registry 2. Circ J. 2016;80(4):843-51. 

39）Watanabe E, Yamamoto M, Kodama I, Inoue H, Atarashi H, Okumura K, Yamashita T, Lip GY, Kodani E, Okuyama Y, Chishaki A, Kiyono K, Origasa H; J-RHYTHM Registry Investigators. Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. Int J Cardiol. 2016 Jun 1;212:311-7. 

40）Yamashita T, Koretsune Y, Yang Y, Chen SA, Chung N, Shimada YJ, Kimura T, Miyazaki K, Abe K, Mercuri M, Ruff CT, Giugliano RP. Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation　- An ENGAGE AF-TIMI 48 Subanalysis. Circ J. 2016;80(4):860-9. 

41）Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry. J Stroke Cerebrovasc Dis. 2016 Mar;25(3):585-99. 

42）Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Otsuka T, Tomita H, Origasa H; J‐RHYTHM Registry Investigators. Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry. J Am Heart Assoc. 2016 Sep 12;5(9).

43）Ikeda T, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Shimokawa H. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation. Tohoku J Exp Med. 2016 Dec;240(4):259-268.

44）Kumagai N, Nusser JA, Inoue H, Okumura K, Yamashita T, Kubo T, Kitaoka H, Origasa H, Atarashi H; J-RHYTHM Registry Investigators. Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Am J Cardiol. 2017 Jul 15;120(2):230-235.

45）Inoue H, Atarashi H, Okumura K, Yamashita T, Fukuzawa M, Shiosakai K, Kimura T. Heart rate control by carvedilol in Japanese patients with chronic atrial fibrillation: The AF Carvedilol study. J Cardiol. 2017 Jan;69(1):293-301. 

46）Shiga T, Yoshioka K, Watanabe E, Omori H, Yagi M, Okumura Y, Matsumoto N, Kusano K, Oshiro C, Ikeda T, Takahashi N, Komatsu T, Suzuki A, Suzuki T, Sato Y, Yamashita T; AF-QOL study investigators. Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide. J Arrhythm. 2017 Aug;33(4):310-317.

47）Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):59-68.

48）Okumura K, Lip GYH, Akao M, Tanizawa K, Fukuzawa M, Abe K, Akishita M, Yamashita T. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study. Am Heart J. 2017 Dec;194:99-106.

49）Shimokawa H, Yamashita T, Uchiyama S, Kitazono T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Atarashi H, Inoue H. The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Int J Cardiol. 2018 May 1;258:126-132.

50）Uchiyama S, Atarashi H, Inoue H, Kitazono T, Yamashita T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Shimokawa H. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study. Heart Vessels. 2019 Jan;34(1):141-150.

51）Inoue H, Kodani E, Atarashi H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Renal Dysfunction Affects Anticoagulation Control With Warfarin and Outcomes in Japanese Elderly Patients With Non-Valvular Atrial Fibrillation. Circ J. 2018 Aug 24;82(9):2277-2283.

52）Inoue H, Kodani E, Atarashi H, Okumura K, Yamashita T, Okuyama Y, Origasa H; J-RHYTHM Registry Investigators. Time in Therapeutic Range and Disease Outcomes in Elderly Japanese Patients With Nonvalvular Atrial Fibrillation. Circ J. 2018 Sep 25;82(10):2510-2517.

53）Yamashita T, Ikeda T, Akita Y. Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study). J Cardiol. 2019 May;73(5):386-393.

54）Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, Yamashita T, Taniguchi A, Fukaya T; J-Dabigation Surveillance Investigators. Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance. J Cardiol. 2019 Jun;73(6):507-514.

55）Koretsune Y, Kusakawa K, Harada KH, Koizumi A, Uchiyama S, Atarashi H, Okumura K, Yasaka M, Yamashita T, Taniguchi A, Fukaya T, Inoue H; for J-dabigatran surveillance and JAPAF study investigators. Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study. Cardiol Ther. 2019 Jun;8(1):43-54. 

56）Yamashita T, Koretsune Y, Ishikawa M, Shiosakai K, Kogure S. Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results. J Arrhythm. 2018 Dec 26;35(1):121-129.

57）Yamashita T, Hagii J, Morishima Y, Akasaka T, Matsumoto T, Kimura T. Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication). Thromb J. 2019 Feb 15;17:3. 

58）Sakuma I, Uchiyama S, Atarashi H, Inoue H, Kitazono T, Yamashita T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Shimokawa H. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. Heart Vessels. 2019 Nov;34(11):1839-1851.

59）Kodani E, Inoue H, Atarashi H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Impact of Digitalis Use on Mortality in Japanese Patients With Non-Valvular Atrial Fibrillation　- A Subanalysis of the J-RHYTHM Registry. Circ J. 2019 Jul 25;83(8):1644-1652.

60）Ikeda T, Shiga T, Shimizu W, Kinugawa K, Sakamoto A, Nagai R, Daimon T, Oki K, Okamoto H, Yamashita T; J-Land II Study Investigators. Efficacy and Safety of the Ultra-Short-Acting β1-Selective Blocker Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhymias　- Outcomes of J-Land II Study. Circ J. 2019 Jun 25;83(7):1456-1462.

61）Yamashita T, Nakasu Y, Mizutani H, Sumitani K. A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. J Cardiol. 2019 Nov;74(5):418-425.

＜ANAFIE関連論文＞
Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Akishita M, Hasebe N, Kario K, Mizokami Y, Nagata K, Nakamura M, Terauchi Y, Yamamoto T, Teramukai S, Kimura T, Kaburagi J, Takita A. Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry. J Cardiol. 2018 Oct;72(4):300-306. 

Koretsune Y, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Teramukai S, Kimura T, Kaburagi J, Takita A, Inoue H. Baseline Demographics and Clinical Characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. Circ J. 2019 Jun 25;83(7):1538-1545. 

＜J-ELD AF関連論文＞
Akao M, Yamashita T, Okumura K; J-ELD AF Investigators. Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. J Cardiol. 2016 Dec;68(6):554-558. 

Relationship between the prognostic value of ventilatory efficiency and age in patients with heart failure.
Kato Y, Suzuki S, Uejima T, Semba H, Nagayama O, Hayama E, Arita T, Yagi N, Kano H, Matsuno S,
Otsuka T, Oikawa Y, Kunihara T, Yajima J, Yamashita T.
Eur J Prev Cardiol. 2018 May;25(7):731-739. doi: 10.1177/2047487318758775. Epub 2018 Feb 13.
PMID:29433335

Prognostic value of the heart rate profile during exercise in patients with atrial fibrillation.
Aihara K, Kato Y, Suzuki S, Arita T, Yagi N, Semba H, Kano H, Matsuno S, Otsuka T, Uejima T, Oikawa Y, Kunihara T, Yajima J, Yamashita T.
Eur J Prev Cardiol. 2018 Oct;25(15):1634-1641. doi: 10.1177/2047487318797398. Epub 2018 Aug 30.
PMID:30160179

Eleven-year temporal trends of clinical characteristics and long-term outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndrome in the Shinken database.
Numao Y, Suzuki S, Kano H, Yajima J, Oikawa Y, Matsuno S, Arita T, Yagi N, Semba H, Kato Y, Otsuka T, Uejima T, Yamashita T.
Heart Vessels. 2019 Feb;34(2):199-207. doi: 10.1007/s00380-018-1229-y. Epub 2018 Jul 24.
PMID:30043155

学会・研究会発表

Development of Risk Models for Mortality and Morbidity by Artificial Intelligence: Shinken Database Analysis
Suzuki S, Yamashita T, Sakama T, Otsuka T, Yagi N, Arita T, Semba H, Kano H, Matsuno S, Kato Y, Uejima T, Oikawa Y, Matsuhama M, Yajima J
The 83th Annual Scientific Meeting of the Japanese Circulation Society Featured Research Session
March 29,2019.

Preserved Ejection Fraction: Shinken Database Analysis
張 俊逸, 加藤祐子, 有田卓人, 八木直治, 仙波宏章, 嘉納寛人, 鈴木信也, 松野俊介, 上嶋徳久, 大塚崇之, 及川裕二, 矢嶋純二, 山下武志
第 83 回日本循環器学会学術集会 2019 年 3 月 29 日

Decrease in eGFR and Cardiovascular Events in Patients Who Visited a Cardiovascular Hospital : Shinken Database Analysis
藤澤友輝, 鈴木信也, 八木直治, 有田卓人, 大塚崇之, 仙波宏章, 嘉納寛人, 松野俊介, 加藤祐子, 上嶋徳久, 及川裕二, 松濱 稔, 矢嶋純二, 山下武志
第 83 回日本循環器学会学術集会 2019 年 3 月 30 日

Gender Difference and Thirteen-year Temporal Trends in 3-year Outcomes after Percutaneous Coronary Intervention from Shinken Database
沼尾嘉美, 鈴木信也, 嘉納寛人, 矢嶋純二, 及川裕二, 松野俊介, 有田卓人, 八木直治, 仙波宏章, 加藤祐子, 大塚崇之, 上嶋徳久, 松濱 稔, 山下武志
第 83 回日本循環器学会学術集会 2019 年 3 月 30 日

Seasonal Variations in Incidence of Cerebral Infraction, Intracranial and Extracranical Hemorrhage in Atrial Fibrillation; Shinken Database Analysis
大井田充範, 鈴木信也, 有田卓人, 八木直治, 大塚崇之, 仙波宏章, 加藤祐子, 嘉納寛人, 松野俊介, 上嶋徳久, 及川裕二, 松濱 稔, 矢嶋純二, 山下武志
第 83 回日本循環器学会学術集会 2019 年 3 月 30 日

Estimated Glomerular Filtration Rate and Proteinuria Synergistically Predict Atrial Fibrillation,
Thromboembolism, Heart Failure Events, and Mortality: Shinken Database Analysis
大井田充範, 鈴木信也, 有田卓人, 八木直治, 大塚崇之, 仙波宏章, 加藤祐子, 嘉納寛人, 松野俊介, 上嶋徳久, 及川裕二, 松濱 稔, 矢嶋純二, 山下武志
第 83 回日本循環器学会学術集会 2019 年 3 月 31 日

Estimated Glomerular Filtration Rate as a Predictor of Mortality and Morbidity in Patients Visiting a Cardiovascular Hospital: Shinken Database Analysis
Fukumoto K, Suzuki S, Arita T, Yagi N, Otsuka T, Senba H, Kano H, Matsuno S, Kato Y, Oikawa Y,
Matsuhama M, Yajima J, Yamashita T.
The 83th Annual Scientific Meeting of the Japanese Circulation Society March 31,2019.

Use of Anticoagulation and Incidence of Thrombotic and Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention (PCI):Shinken Database Analysis
新井 陸, 鈴木信也, 嘉納寛人, 矢嶋純二, 及川裕二, 松野俊介, 有田卓人, 八木直治, 仙波宏章, 加藤祐子,
大塚崇之, 上嶋徳久, 山下武志
第 83 回日本循環器学会学術集会 2019 年 3 月 31 日